Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVAX Prostate
- Development stage
- Phase 2
- Lead developer
- ANI Pharmaceuticals
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Adoptive Cell Transfer → Cell Therapies
- Administration
- Subcutaneous, Intradermal
01
Overview
**GVAX Prostate** is an investigational allogeneic cancer cellular vaccine for prostate cancer, consisting of irradiated prostate cancer cell lines (primarily LNCaP and PC-3) genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF enhances dendritic cell recruitment and activation at the vaccination site, promoting antigen presentation from whole tumor cells to elicit both T-cell and B-cell immune responses against prostate cancer antigens, including those from lymph node and bone metastases. Developed initially by Cell Genesys, it demonstrated antitumor activity in preclinical rat and transgenic models, safety and immune responses in early clinical trials, and improved median overall survival (e.g., 26-35 months vs. predicted 19-22 months) in phase II studies of metastatic castration-resistant prostate cancer (mCRPC), though phase III trials (VITAL-1 and VITAL-2) did not meet endpoints and were halted.
- Brand names
- GVAX
- Other names
- GVAX prostate cancer vaccine
Beyond the preview
Go deeper on GVAX Prostate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVAX Prostate.